دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Polypharmacy in multiple sclerosis: More is not necessarily better
Dennis Bourdette and Megan Herink
doi : 10.1177/13524585221129964
Volume 29 Issue 1, January 2023
Otto van Eikema Hommes – 7 February 1932 – 16 August 2022
Ludwig Kappos , Frederik Barkhof and Bernard Uitdehaag
Addressing me in the context of my disease: Why it is so complicated
Lisa B Grech
doi : 10.1177/13524585221135502
Addressing a person in the context of their disease must be done respectfully. As a person with multiple sclerosis (MS), my preference is to be referred to as such. Some people with MS refer to themselves as MSers, MS warriors, MS sufferers, and that’s fine.
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society
Sandra Vukusic , Clarisse Carra-Dalliere , Jonathan Ciron , Elisabeth Maillart , Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, Bertrand Bourre, David Laplaud, Géraldine Androdias, Caroline Bensa, Kevin Bigaut , Damien Biotti , Pierre Branger, Olivier Casez, Mikael Cohen , Elodie Daval, Romain Deschamps, Cécile Donze, Anne-Laure Dubessy, Cécile Dulau, Françoise Durand-Dubief, Maxime Guillaume, Benjamin Hebant, Laurent Kremer, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf , Eric Manchon, Guillaume Mathey, Xavier Moisset , Alexis Montcuquet, Julie Pique, Thomas Roux , Romain Marignier and Christine Lebrun-Frenay; on behalf the French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP)*
doi : 10.1177/13524585221129472
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS).
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society
Sandra Vukusic , Romain Marignier , Jonathan Ciron , Bertrand Bourre, Mikael Cohen , Romain Deschamps, Maxime Guillaume, Laurent Kremer, Julie Pique, Clarisse Carra-Dalliere , Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, David Laplaud, Géraldine Androdias, Caroline Bensa, Kevin Bigaut , Damien Biotti , Pierre Branger, Olivier Casez, Elodie Daval, Cécile Donze, Anne-Laure Dubessy, Cécile Dulau, Françoise Durand-Dubief, Benjamin Hebant, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf , Eric Manchon, Guillaume Mathey, Xavier Moisset , Alexis Montcuquet, Thomas Roux , Elisabeth Maillart and Christine Lebrun-Frenay; on behalf the French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP)*
doi : 10.1177/13524585221130934
In 2020, the French Multiple Sclerosis (MS) Society (SFSEP) decided to develop a national evidence-based consensus on pregnancy in MS. As neuromyelitis optica spectrum disorders (NMOSD) shares a series of commonalities with MS, but also some significant differences, specific recommendations had to be developed.
Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood
Arlette L Bruijstens , Christoph Stingl, Coşkun Güzel, Marcel P Stoop, Yu Yi M Wong, E Daniëlle van Pelt, Brenda L Banwell*, Amit Bar-Or*, Theo M Luider* and Rinze F Neuteboom * ; Dutch Pediatric MS and ADEM Study Group; Canadian Pediatric Demyelinating Disease Network
doi : 10.1177/13524585221125369
Pediatric-onset multiple sclerosis (POMS) represents the earliest stage of disease pathogenesis. Investigating the cerebrospinal fluid (CSF) proteome in POMS may provide novel insights into early MS processes.
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients
Christoph Friedli , Franca Wagner , Helly Noemi Hammer, Nicole Kamber, Roland Wiest, Lara Diem , Andrew Chan, Anke Salmen and Robert Hoepner
doi : 10.1177/13524585221122210
Leptomeningeal inflammation in patients with multiple sclerosis (MS) mainly affects meningeal B-cell follicle-like structures linked to cortical and subpial lesions and can be visualized as leptomeningeal enhancement (LME).
Progressive motor impairment from “critical� demyelinating lesions of the cervicomedullary junction
Caitlin S Jackson-Tarlton, Eoin P Flanagan , Steven Anthony Messina, Benan Barakat , Rowaid Ahmad, Orhun H Kantarci, Brian G Weinshenker and B Mark Keegan
doi : 10.1177/13524585221114438
Progressive motor impairment anatomically associated with a “critical� lesion has been described in primary demyelinating disease. Most “critical� lesions occur within the spinal cord.
Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis
Myrte Strik , Anand JC Eijlers, Iris Dekker, Tommy AA Broeders, Linda Douw, Joep Killestein, Scott C Kolbe , Jeroen JG Geurts and Menno M Schoonheim
doi : 10.1177/13524585221125372
Upper and lower limb disabilities are hypothesized to have partially independent underlying (network) disturbances in multiple sclerosis (MS).
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
Jeffrey A Cohen , Fred D Lublin, Christoper Lock, Daniel Pelletier, Tanuja Chitnis , Munish Mehra, Yael Gothelf, Revital Aricha, Stacy Lindborg, Chaim Lebovits, Yossef Levy, Afsaneh Motamed Khorasani and Ralph Kern
doi : 10.1177/13524585221122156
Autologous mesenchymal stem cell neurotrophic factor–secreting cells (NurOwn®) have the potential to modify underlying disease mechanisms in progressive multiple sclerosis (PMS).
Polypharmacy and multiple sclerosis: A population-based study
Anibal Chertcoff , Huah Shin Ng , Feng Zhu, Yinshan Zhao and Helen Tremlett
doi : 10.1177/13524585221122207
Little is known about polypharmacy and multiple sclerosis (MS).
Prediction of relapse activity when switching to cladribine for multiple sclerosis
Michael Zhong, Anneke van der Walt , Mastura Monif , Suzanne Hodgkinson, Sara Eichau , Tomas Kalincik , Jeannette Lechner-Scott , Katherine Buzzard, Olga Skibina, Vincent Van Pesch, Ernest Butler, Julie Prevost, Marc Girard, Jiwon Oh , Helmut Butzkueven * and Vilija Jokubaitis* ; on behalf of the MSBase Study Group
doi : 10.1177/13524585221111677
Patients with relapsing–remitting multiple sclerosis commonly switch between disease-modifying therapies (DMTs). Identifying predictors of relapse when switching could improve outcomes.
Recurrent disability progression endpoints in multiple sclerosis clinical trials
Alexandra Bühler , Marcel Wolbers, Fabian Model, Qing Wang, Shibeshih Belachew , Marianna Manfrini, Johannes Lorscheider, Ludwig Kappos and Jan Beyersmann
doi : 10.1177/13524585221125382
The current standard endpoint to assess disability accumulation in multiple sclerosis (MS) clinical trials is the time to the first confirmed disability progression, which excludes subsequent progression events. Including recurrent progression events may permit a more comprehensive assessment of treatment effects on disability progression.
A new look at cognitive functioning in pediatric MS
Lauren B Krupp , Emmanuelle Waubant, Michael Waltz, T Charles Casper, Anita Belman, Yolanda Wheeler, Jayne Ness, Jennifer Graves, Mark Gorman, Leslie Benson, Soe Mar, Manu Goyal, Teri Schreiner, Bianca Weinstock-Guttman , Moses Rodriguez, Jan-Mendelt Tillema, Timothy Lotze, Greg Aaen, Mary Rensel , John Rose, Tanuja Chitinis , Allan George, Leigh E Charvet and the US Network of Pediatric MS Centers
doi : 10.1177/13524585221123978
Cognitive involvement in pediatric multiple sclerosis (MS) relative to adult MS is less defined. This study advances our understanding by measuring cognitive performances in pediatric MS, adult MS, and pediatric healthy controls.
Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient
Claudia Pestchanker , Melina Diaconchuk, Paula Lopez, MarÃa Rosa Montaño, William Romero, Guillermo Zalazar and Edgar Carnero Contentti
doi : 10.1177/13524585221137231
Recently, satralizumab (interleukin-6 receptor blocker) was approved for seropositive neuromyelitis optica spectrum disorder (NMOSD) patients. In SAkuraSky trial, mild neutropenia was reported in 15% of patients under satralizumab. Most neutropenias were transient; grade 3–4 was not related to serious infections. So far, no severe neutropenia (<100 cell/mm3) has been reported worldwide.
Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient�Commentary
Cristina Valencia-Sanchez
